Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma
17 December 2020
Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma
Leading international law firm Clifford Chance has advised ICG Strategic Equity, as the lead investor, in CapVest’s GP-led secondary in respect of Curium Pharma, one of the largest single-asset secondary transactions to take place in 2020.
Dual-headquartered in Paris and London, with manufacturing facilities across Europe and the United States, Curium Pharma is a global vertically integrated developer, manufacturer and distributer of medical radioisotopes and radiopharmaceuticals for use in diagnostic imaging and therapeutic procedures. It was reportedly the subject of a highly contested sale process earlier in this year, before London-based sponsor CapVest decided to explore a secondary process after the onset of the global pandemic.